Tandem Diabetes Care (LTS:0M0F) Growth Rank: 8 (As of Sep. 21, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
68 GF Score
Price $17.06
GF Value $24.42
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Growth Rank?

Tandem Diabetes Care LTS:0M0F -1.33% 68 Growth Rank is 8 as of Sep. 21, 2026, which is at its 10-year median of 8.00. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $24.42 (Possible Value Trap). The stock has 5 warning signs investors should review.

Tandem Diabetes Care has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Tandem Diabetes Care Growth Rank Related Terms

LTS:0M0F vs CNMD, ATEC, ENOV: Growth Rank Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tandem Diabetes Care Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Growth Rank distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Growth Rank falls into.


LTS:0M0F
68GF Score
Tandem Diabetes Care Inc LTS:0M0F
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Tandem Diabetes Care (LTS:0M0F) has a Growth Rank of 8 as of Sep. 21, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Tandem Diabetes Care and its competitors. This is near median its historical median of 8.00. Over the past decade, Tandem Diabetes Care's Growth Rank has ranged from 1.00 to 9.00.
Is Tandem Diabetes Care's Growth Rank too high?
Tandem Diabetes Care's current Growth Rank of 8 is near median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Growth Rank compare to CNMD and ATEC?
Tandem Diabetes Care's Growth Rank of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Tandem Diabetes Care's own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Growth Rank is 8, which is near median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $24.42, compared to a current price of $17.06 — trading 30.1% below its estimated fair value. The current Growth Rank is 8, which is near median its 10-year median of 8.00. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Growth Rank is 8 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $17.06 is trading 30.1% below its estimated GF Value™ of $24.42. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • Growth Rank: 8 (near median its 10-year median of 8.00)
  • GF Value™: $24.42 vs. price of $17.06 (30.1% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score

Get the complete analysis for LTS:0M0F

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.06
Price
$24.42
GF Value